• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Bausch + Lomb (BLCO) Undervalued After Its Profit Return And Guidance Raise?

    Simply Wall St·10/31/2026 05:38:53
    语音播报

    Bausch + Lomb (BLCO) just delivered a return to profitability in its third quarter, with revenue across all segments and margins supporting a higher full year outlook and raised guidance.

    The Q3 earnings beat and guidance raise have come alongside a sharp shift in sentiment, with Bausch + Lomb’s share price delivering a 7 day return of 14.48% and a 30 day share price return of 17.65%, even after a 1 day decline of 1.96%. The 1 year total shareholder return of 33.87% and 3 year total shareholder return of 16.69% point to momentum that has been building rather than fading.

    Capitalize on Bausch + Lomb's renewed profitability momentum by scanning hand-picked eyecare peers and broader health companies in the 18 high quality undiscovered gems.

    Bausch + Lomb has sprinted ahead of its own guidance, and the share price has moved quickly to reflect that shift. Does the gap between today’s US$20 quote and fair value estimates still leave meaningful room on the table?

    Most Popular Narrative: 5.4% Undervalued

    On the most followed view, Bausch + Lomb screens as slightly undervalued, with a fair value of $21.14 against the recent $20 close. This puts the current rally in context rather than calling it excessive.

    Disciplined execution under the Vision 27 financial excellence program, including SG&A mix optimization, manufacturing efficiencies and focused R&D spend on near to mid term launch assets, is expected to support adjusted EBITDA growth above sales growth and drive expanding net margins and earnings power.

    See why 3 investors see Bausch + Lomb as 5% undervalued.

    Result: Fair Value of $21.14 (UNDERVALUED)

    Still, the Bausch + Lomb story leans heavily on future margin expansion and late stage dry eye trials, and any stumble there could quickly challenge the undervaluation view.

    Find out about the key risks to this Bausch + Lomb narrative.

    Next Steps

    Seeing both optimism and real risks around Bausch + Lomb in this piece, you should move quickly, review the underlying figures, and weigh the 3 key rewards and 1 important warning sign in the 3 key rewards and 1 important warning sign.

    Looking for more Bausch + Lomb sized opportunities?

    If you stop with Bausch + Lomb, you miss a wider field of potential ideas. Put the same energy into finding your next edge with a few targeted screens.